Annexin Pharmaceuticals AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANNX.ST research report →
Companywww.annexinpharma.com/sv
Annexin Pharmaceuticals AB (publ), a biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. The company develops ANXV, a human recombinant protein. It offers Annexin A5 to protect and repair blood vessels and counteract inflammation.
- CEO
- Anders Haegerstrand
- IPO
- 2017
- Employees
- 4
- HQ
- Stockholm, SE
Price Chart
Valuation
- Market Cap
- $98.47M
- P/E
- -2.50
- P/S
- 0.00
- P/B
- 6.83
- EV/EBITDA
- -2.05
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -131.29%
- ROIC
- -273.65%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-36,893,000 · 26.58%
- EPS
- $-5.58 · -4972.73%
- Op Income
- $-36,313,000
- FCF YoY
- 26.23%
Performance & Tape
- 52W High
- $39.00
- 52W Low
- $11.65
- 50D MA
- $14.29
- 200D MA
- $20.46
- Beta
- 0.24
- Avg Volume
- 5.12K
Get TickerSpark's AI analysis on ANNX.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ANNX.ST Coverage
We haven't published any research on ANNX.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ANNX.ST Report →